On 25 June 2025, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) received an eligibility-to-list letter (“ETL”) from the Singapore Exchange Securities Trading Limited (the “SGX-ST”) in respect of the Proposed Secondary Listing and, subject to fulfilment of the conditions set out therein, the Shares are expected to be listed and to commence trading on the SGX-ST on around 15 July 2025. The ETL is not an indication of the merits of the Proposed Secondary Listing, the Group and/or the Shares.
The Proposed Secondary Listing will not involve issuance of new Shares, and the Shares will continue to be listed and traded on the Hong Kong Stock Exchange thereafter.
The Directors believe that upon completion of the Proposed Secondary Listing on the SGX-ST, the Group will be able to attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia, thereby optimizing the shareholder structure. At the same time, it will also have a more profound impact on the Group’s business development in Southeast Asia and the Middle East. The Group has established Singapore as its regional headquarters for its Southeast Asia and Middle East business, and has set up companies in Singapore covering the entire pharmaceutical value chain of R&D, manufacturing, commercialization and investment, including CMS R&D as the international independent R&D company, PharmaGend as the pharmaceutical manufacturing CMO/CDMO company, Rxilient as the pharmaceutical development, registration and commercialization company, and Singapore Venture Capital as the industrial investment company. These companies work together to provide Southeast Asian patients with more high-quality and affordable treatment options, contribute to the development of the pharmaceutical industry chain in Southeast Asia, enhance the Group’s global reputation and market position, promote the implementation of the Group’s “Glocalization” strategy, and bring additional growth to the Group.
The Company will make further announcements with respect to the Proposed Secondary Listing as and when necessary in compliance with the applicable laws and regulations.
The Proposed Secondary Listing is subject to the fulfilment of the conditions set out in the ETL. As such, there is no assurance that the Proposed Secondary Listing will proceed to completion. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.
Please visit the following link: https://web.cms.net.cn/wp-content/uploads/2025/06/e-2-1.pdf, to access the introductory document published on the SGX-ST website on 27 June 2025 in connection with the Company’s proposed secondary listing.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.